Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium

SAN DIEGO, June 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
May 28, 2014 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

SAN DIEGO, May 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
May 13, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2014 Financial Results

Phase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA IND Submission for...
May 06, 2014 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014

SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
April 30, 2014 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference

SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
April 23, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients

SAN DIEGO, April 23, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
April 10, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics

SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
March 17, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Phase 2 PUMA Study of PROHEMA® Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA® in Lysosomal Storage Disorders to Begin in 2H14 Encouraging Clinical Data Published...
March 17, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors

SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
March 12, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies

First Patient Enrolled in PUMA Study Approved for Conduct at Ten Leading U.S. Centers Interim Data Expected in 2H14 SAN DIEGO, March 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc....